Cytozen: US Cancer Society’s Prostate & Bone Cancer Research
Cytozen’s Liquid Biopsy Technology Gains Recognition at AACR 2025
Table of Contents
- Cytozen’s Liquid Biopsy Technology Gains Recognition at AACR 2025
- cytozens Liquid Biopsy Technology: A Deep Dive into the Future of Cancer Diagnostics
- What is Cytozen and What Does it Specialize In?
- What is a Liquid Biopsy?
- What Did Cytozen showcase at the AACR 2025 Meeting?
- What Technology Does Cytozen Use?
- How Does ddPCR Compare to Traditional Tissue Biopsies?
- what are the benefits of using non-invasive blood tests for multiple myeloma?
- What is the Market Potential for Cytozen’s Technologies?
- What Applications of Cytozen’s Technology Are Being explored for Commercialization?
- What Partnerships Has Cytozen Formed?
- What is a Companion diagnostic solution?
- What Are Cytozen’s Expansion Plans?
- What is CDx?
- What Specific Actions Are Being Taken in Japan?
- What Did a Cytozen Official State About the AACR 2025 Meeting?
- Key Advantages of Cytozen’s DDPCR Technology
CHICAGO (AP) — Cytozen, a company specializing in CTC-based liquid biopsies, showcased its latest research on prostate cancer and multiple myeloma at the American Association for Cancer Research (AACR) 2025 annual meeting in Chicago, receiving validation from multinational pharmaceutical firms.
DDPCR Technology for Enhanced Cancer Diagnosis
cytozen presented clinical data on its droplet digital PCR (DDPCR) molecular diagnostic technology, which analyzes circulating tumor cells (CTCs) in blood samples. The company asserts this technology offers improvements over traditional tissue biopsies, which have a lower diagnostic success rate (20-25%) and can cause side effects such as pain, hematuria, and bloody stools. The DDPCR method offers a viable alternative for patients who are not suitable candidates for traditional biopsies.
Non-Invasive Blood Tests for multiple myeloma
The company also highlighted the potential of its technology to replace bone marrow tests for diagnosing multiple myeloma. According to Cytozen, using non-invasive blood tests can ease the burden on patients and enable more precise monitoring of recurrence and minimal residual disease (MRD), which often requires repeated testing. Discussions focused on the commercialization of this blood-based diagnostic approach.
Market Potential for Prostate Cancer and Multiple Myeloma Diagnostics
Prostate cancer and multiple myeloma represent significant market opportunities. The American Cancer Society identifies prostate cancer as the second leading cause of cancer death in U.S. men. BCC Research projects the global market for prostate cancer screening and diagnostics will reach approximately $20 billion by 2028.
The multiple myeloma diagnostic market is also poised for considerable growth. PharmiWeb estimates the market at $13 billion in 2023, with projections reaching $31 billion by 2032, representing an average annual growth rate of 10.5%.
Strategic Partnerships and Commercialization
The AACR 2025 meeting facilitated discussions between Cytozen and leading U.S. hospitals regarding potential collaborations. These discussions centered on commercializing clinical applications of cytozen’s technology, including patient monitoring, drug response prediction, and treatment effect evaluation. Furthermore,a multinational pharmaceutical company specializing in multiple myeloma drug progress expressed interest in using Cytozen’s CTC analysis platform as a companion diagnostic solution,potentially leading to joint research or clinical partnerships.
Expansion into the Japanese Market
Cytozen is also exploring expansion into the Japanese precision medicine market.The company engaged in discussions with top Japanese cancer hospitals and multinational pharmaceutical companies about developing CDx-based new drugs using Cytozen’s platform with 3D organoids. Follow-up meetings with global pharmaceutical companies from the U.S., Japan, and Korea are planned to further explore collaborations related to the CTC platform.
Company Statement
According to a Cytozen official, the AACR 2025 meeting served as a platform to gain recognition from global experts for its diagnostic platform. The company anticipates accelerated expansion of its overseas business operations in the United States and Japan.
cytozens Liquid Biopsy Technology: A Deep Dive into the Future of Cancer Diagnostics
What is Cytozen and What Does it Specialize In?
Cytozen is a company specializing in circulating tumor cell (CTC)-based liquid biopsies. They develop and utilize advanced technologies for cancer diagnostics and monitoring.
What is a Liquid Biopsy?
A liquid biopsy is a non-invasive medical test that analyzes a blood sample to detect and analyze cancer cells or their genetic material. This contrasts with traditional tissue biopsies, which involve removing a tissue sample, often through surgery.
What Did Cytozen showcase at the AACR 2025 Meeting?
Cytozen presented its latest research on prostate cancer and multiple myeloma at the American Association for cancer Research (AACR) 2025 annual meeting in Chicago.
What Technology Does Cytozen Use?
Cytozen’s primary technology is droplet digital PCR (ddPCR). This molecular diagnostic technology analyzes circulating tumor cells (CTCs) in blood samples.
How Does ddPCR Compare to Traditional Tissue Biopsies?
Cytozen’s ddPCR technology offers several potential advantages over traditional tissue biopsies:
Less Invasive: Requires only a blood draw, avoiding the pain and potential complications associated with tissue biopsies.
Higher Diagnostic Success: Traditional biopsies have a success rate of only 20-25%.
Better suited for certain patients: The DDPCR method offers a viable alternative for patients who are not suitable candidates for traditional biopsies.
what are the benefits of using non-invasive blood tests for multiple myeloma?
Using non-invasive blood tests can:
Ease the burden on patients
Enable more precise monitoring of recurrence and minimal residual disease (MRD)
What is the Market Potential for Cytozen’s Technologies?
There is a significant market opportunity for Cytozen’s technologies, notably in the areas of:
Prostate Cancer: the global market for prostate cancer screening and diagnostics is projected to reach approximately $20 billion by 2028.
Multiple Myeloma: The multiple myeloma diagnostic market is estimated at $13 billion in 2023, with projections reaching $31 billion by 2032 (an average annual growth rate of 10.5%).
What Applications of Cytozen’s Technology Are Being explored for Commercialization?
Cytozen is exploring the commercialization of its technology for various clinical applications, including:
Patient monitoring
Drug response prediction
Treatment effect evaluation
What Partnerships Has Cytozen Formed?
Cytozen has engaged in discussions with leading U.S. hospitals regarding potential collaborations focused on commercializing its technology. Moreover,a multinational pharmaceutical company specializing in multiple myeloma drug progress expressed interest in using Cytozen’s CTC analysis platform as a companion diagnostic solution,which could lead to joint research or clinical partnerships.
What is a Companion diagnostic solution?
A companion diagnostic is a medical device, often an in vitro diagnostic device, that provides information essential for the safe and effective use of a corresponding therapeutic product. This type of diagnostic solution would work with a drug to identify patients who would be most appropriate for a specific treatment.
What Are Cytozen’s Expansion Plans?
Cytozen is looking to expand into the Japanese precision medicine market.
What is CDx?
CDx stands for companion diagnostics. They are medical devices, frequently enough in-vitro diagnostic (IVD) devices, that are used to identify patients who are most likely to benefit from or be harmed by a specific therapeutic treatment.
What Specific Actions Are Being Taken in Japan?
cytozen engaged in discussions with top Japanese cancer hospitals and multinational pharmaceutical companies about developing CDx-based new drugs using Cytozen’s platform with 3D organoids.Follow-up meetings with global pharmaceutical companies from the U.S.,Japan,and Korea are planned regarding the CTC platform.
What Did a Cytozen Official State About the AACR 2025 Meeting?
According to a Cytozen official, the AACR 2025 meeting served as a platform to gain recognition from global experts for its diagnostic platform. The company anticipates accelerated expansion of its overseas business operations in the United States and Japan.
Key Advantages of Cytozen’s DDPCR Technology
| Feature | Cytozen’s DDPCR (Liquid Biopsy) | Traditional Tissue Biopsy |
| ————————— | ———————————————— | —————————————- |
| Invasiveness | Non-invasive (blood draw) | Invasive (tissue removal) |
| Success Rate | Higher (data not explicitly provided in the text, but implied to be greater compared to 20-25%) | Lower (20-25%) |
| Patient suitability | Suitable for patients not eligible for traditional biopsy. | Restrictions based on patient condition. |
| Monitoring Capabilities | Superior for monitoring recurrence and MRD | Limited |
| Patient Experience | Less painful, fewer side effects. | Pain, potential side effects. |